These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

406 related items for PubMed ID: 31625395

  • 1. Efficacy and Safety of Vasopressin as First-Line Treatment of Distributive and Hemorrhagic Shock States.
    Haan BJ, Cadiz ML, Natavio AM.
    Ann Pharmacother; 2020 Mar; 54(3):213-218. PubMed ID: 31625395
    [Abstract] [Full Text] [Related]

  • 2. Hemodynamic Instability Secondary to Vasopressin Withdrawal in Septic Shock.
    Bissell BD, Magee C, Moran P, Bastin MLT, Flannery AH.
    J Intensive Care Med; 2019 Sep; 34(9):761-765. PubMed ID: 28750598
    [Abstract] [Full Text] [Related]

  • 3. Fixed-dose vasopressin compared with titrated dopamine and norepinephrine as initial vasopressor therapy for septic shock.
    Hall LG, Oyen LJ, Taner CB, Cullinane DC, Baird TK, Cha SS, Sawyer MD.
    Pharmacotherapy; 2004 Aug; 24(8):1002-12. PubMed ID: 15338849
    [Abstract] [Full Text] [Related]

  • 4. Mortality, Morbidity, and Costs After Implementation of a Vasopressin Guideline in Medical Intensive Care Patients With Septic Shock: An Interrupted Time Series Analysis.
    Bauer SR, Sacha GL, Reddy AJ.
    Ann Pharmacother; 2020 Apr; 54(4):314-321. PubMed ID: 31679395
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prospective Open-label Trial of Early Concomitant Vasopressin and Norepinephrine Therapy versus Initial Norepinephrine Monotherapy in Septic Shock.
    Hammond DA, Ficek OA, Painter JT, McCain K, Cullen J, Brotherton AL, Kakkera K, Chopra D, Meena N.
    Pharmacotherapy; 2018 May; 38(5):531-538. PubMed ID: 29600824
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and Outcomes After Vasopressin Guideline Implementation in Septic Shock.
    Wu JY, Stollings JL, Wheeler AP, Semler MW, Rice TW.
    Ann Pharmacother; 2017 Jan; 51(1):13-20. PubMed ID: 27630192
    [Abstract] [Full Text] [Related]

  • 9. The Septic Shock 3.0 Definition and Trials: A Vasopressin and Septic Shock Trial Experience.
    Russell JA, Lee T, Singer J, Boyd JH, Walley KR, Vasopressin and Septic Shock Trial (VASST) Group.
    Crit Care Med; 2017 Jun; 45(6):940-948. PubMed ID: 28333757
    [Abstract] [Full Text] [Related]

  • 10. Norepinephrine and Vasopressin Compared With Norepinephrine and Epinephrine in Adults With Septic Shock.
    Menich BE, Miano TA, Patel GP, Hammond DA.
    Ann Pharmacother; 2019 Sep; 53(9):877-885. PubMed ID: 30957512
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Discontinuation of Vasopressin Before Norepinephrine in the Recovery Phase of Septic Shock.
    Hammond DA, McCain K, Painter JT, Clem OA, Cullen J, Brotherton AL, Chopra D, Meena N.
    J Intensive Care Med; 2019 Oct; 34(10):805-810. PubMed ID: 28618919
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Hypotension Risk Based on Vasoactive Agent Discontinuation Order in Patients in the Recovery Phase of Septic Shock.
    Sacha GL, Lam SW, Duggal A, Torbic H, Reddy AJ, Bauer SR.
    Pharmacotherapy; 2018 Mar; 38(3):319-326. PubMed ID: 29328496
    [Abstract] [Full Text] [Related]

  • 17. Effects of continuous vasopressin infusion in patients with septic shock.
    Obritsch MD, Jung R, Fish DN, MacLaren R.
    Ann Pharmacother; 2004 Mar; 38(7-8):1117-22. PubMed ID: 15178740
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and Safety of the Early Addition of Vasopressin to Norepinephrine in Septic Shock.
    Hammond DA, Cullen J, Painter JT, McCain K, Clem OA, Brotherton AL, Chopra D, Meena N.
    J Intensive Care Med; 2019 Mar; 34(11-12):910-916. PubMed ID: 28820036
    [Abstract] [Full Text] [Related]

  • 19. Serious adverse events associated with vasopressin and norepinephrine infusion in septic shock.
    Anantasit N, Boyd JH, Walley KR, Russell JA.
    Crit Care Med; 2014 Aug; 42(8):1812-20. PubMed ID: 24919159
    [Abstract] [Full Text] [Related]

  • 20. Timing of vasopressin initiation and mortality in patients with septic shock: analysis of the MIMIC-III and MIMIC-IV databases.
    Xu J, Cai H, Zheng X.
    BMC Infect Dis; 2023 Apr 03; 23(1):199. PubMed ID: 37013474
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.